Officials from the locally-based biotech company said in March they were delaying construction of the Helix project, which is to house roughly 1,200 employees in an 11-building campus. Phase I was to be finished by the end of next year. But Immunex maintains the corporate headquarters portion of the project will not be necessary if the takeover by Amgen is completed.
Construction began on the Helix Project last January, but following a shortage of its rheumatoid arthritis drug Enbrel, Immunex agreed to a $16 billion takeover by Amgen. Both Amgen and Immunex claim they remain committed to the research and development portion of the project.
Plans for the Helix Project began in 1992. Immunex purchased 29 acres for the site from the Port of Seattle in 1998 and successfully battled environmentalists who feared the project would damage the shoreline.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
